Search:
Tokushima University ⟩ Graduate School of Biomedical Sciences ⟩ 医学域 ⟩ Medical Science ⟩ Internal Medicine ⟩ Department of Respiratory Medicine and Rheumatology ⟩
Tokushima University ⟩ Research Clusters ⟩ Research Clusters ⟩ 2201005 がんの生存戦略の理解と刷新 ⟩ 		(Files for researchmap) [PDF manual] [Auto-propagate to researchmap]

Research

Personal Web Page

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1. Hiroyuki Kozai, Hirokazu Ogino, Atsushi Mitsuhashi, Thi Na Nguyen, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Seidai Satou, Masaki Hanibuchi, Tsutomu Shinohara, Hiroshi Nokihara and Yasuhiko Nishioka :
Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies.,
Thoracic Cancer, Vol.15, No.5, 369-378, 2024.
(Tokushima University Institutional Repository: 119383,   DOI: 10.1111/1759-7714.15200,   PubMed: 38146645)
2. Hiroto Yoneda, Atsushi Mitsuhashi, Aito Yoshida, Hirokazu Ogino, Satoshi Itakura, Thi Na Nguyen, Hiroshi Nokihara, Seidai Satou, Tsutomu Shinohara, Masaki Hanibuchi, Shinji Abe, K Mika Kaneko, Yukinari Kato and Yasuhiko Nishioka :
Antipodoplanin antibody enhances the antitumor effects of CTLA-4 blockade against malignant mesothelioma by natural killer cells.,
Cancer Science, Vol.115, No.2, 357-368, 2024.
(Tokushima University Institutional Repository: 119228,   DOI: 10.1111/cas.16046,   PubMed: 38148492)
3. Yohei Yabuki, Masaki Hanibuchi, Eiji Takeuchi, Takashi Haku, Takanori Kanematsu, Naoki Nishimura, Yuko Toyoda, Atsushi Mitsuhashi, Kenji Otsuka, Seidai Satou, Hisatsugu Goto, Hiroto Yoneda, Hirokazu Ogino, Hiroshi Nokihara, Tsutomu Shinohara and Yasuhiko Nishioka :
A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non-small cell lung cancer.,
Thoracic Cancer, Vol.14, No.32, 3232-3239, 2023.
(Tokushima University Institutional Repository: 119483,   DOI: 10.1111/1759-7714.15115,   PubMed: 37718463)
4. Hiroki Takahashi, Hirokazu Ogino, Hiroki Bando, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka :
FoundationOne CDx detected an uncovered variant of epidermal growth factor receptor exon 19 deletion by Oncomine Dx target test in a patient with lung adenocarcinoma.,
Respiratory Medicine Case Reports, Vol.45, 101893, 2023.
(Tokushima University Institutional Repository: 119403,   DOI: 10.1016/j.rmcr.2023.101893,   PubMed: 37485237)
5. Atsushi Mitsuhashi, Kazuya Koyama, Hirokazu Ogino, Tania Afroj, Thi Na Nguyen, Hiroto Yoneda, Kenji Otsuka, Masamichi Sugimoto, Osamu Kondoh, Hiroshi Nokihara, Masaki Hanibuchi, Hiromitsu Takizawa, Tsutomu Shinohara and Yasuhiko Nishioka :
Identification of fibrocyte cluster in tumors reveals the role in antitumor immunity by PD-L1 blockade.,
Cell Reports, Vol.42, No.3, 112162, 2023.
(Tokushima University Institutional Repository: 118888,   DOI: 10.1016/j.celrep.2023.112162,   PubMed: 36870329)
6. Masaki Hanibuchi, Atsushi Mitsuhashi, Atsuro Saijo, Tatsuya Kajimoto, Seidai Satou, Tetsuya Kitagawa and Yasuhiko Nishioka :
A case of atopic cough with aphonia showed a prominent response to a histamine H1 receptor antagonist.,
The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 281-284, 2023.
(DOI: 10.2152/jmi.70.281,   PubMed: 37164735)
7. T Na Nguyen, Atsushi Mitsuhashi, Hirokazu Ogino, Hiroyuki Kozai, Hiroto Yoneda, Tania Afroj, Seidai Satou, Hiroshi Nokihara, Tsutomu Shinohara and Yasuhiko Nishioka :
S-1 eliminates MDSCs and enhances the efficacy of PD-1 blockade via regulation of tumor-derived Bv8 and S100A8 in thoracic tumor.,
Cancer Science, Vol.114, No.2, 384-398, 2023.
(Tokushima University Institutional Repository: 118295,   DOI: 10.1111/cas.15620,   PubMed: 36285504)
8. Masaki Hanibuchi, Atsushi Mitsuhashi, Tatsuya Kajimoto, Atsuro Saijo, Seidai Satou, Tetsuya Kitagawa and Yasuhiko Nishioka :
Clinical significance of fractional exhaled nitric oxide and periostin as potential markers to assess therapeutic efficacy in patients with cough variant asthma.,
Respiratory Investigation, Vol.61, No.1, 16-22, 2023.
(DOI: 10.1016/j.resinv.2022.10.006,   PubMed: 36463016)
9. Seiya Ichihara, Hirokazu Ogino, Hiroto Yoneda, Keiko Haji, Kozo Kagawa, Kojin Murakami, Masato Mima, Yu Aoi, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Seidai Satou, Hiroshi Nokihara and Yasuhiko Nishioka :
Immune checkpoint inhibitor-related pneumonitis with atypical radiologic features in a patient with anti-aminoacyl-tRNA synthetase antibody.,
Respiratory Medicine Case Reports, Vol.41, 101797, 2023.
(Tokushima University Institutional Repository: 119054,   DOI: 10.1016/j.rmcr.2022.101797,   PubMed: 36583061)
10. Makoto Tobiume, Atsushi Mitsuhashi, Atsuro Saijo, Hirokazu Ogino, Tania Afroj, Hirohisa Ogawa, Hisatsugu Goto, Seidai Satou, Akane Abe, Keiko Haji, Ryohiko Ozaki, Hiromitsu Takizawa and Yasuhiko Nishioka :
Analysis of the chemotactic factors for tumor-infiltrating fibrocytes and their prognostic significances in lung cancer.,
Oncology Letters, Vol.24, No.5, 417, 2022.
(DOI: 10.3892/ol.2022.13537,   PubMed: 36245829)
11. Kenji Otsuka, Hiroshi Nokihara, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Hiroto Yoneda, Hirokazu Ogino and Yasuhiko Nishioka :
Efficacy and safety of second-line chemotherapy for patients with advanced non-small cell lung cancer complicated by interstitial lung disease.,
Thoracic Cancer, Vol.13, No.21, 2978-2984, 2022.
(Tokushima University Institutional Repository: 118615,   DOI: 10.1111/1759-7714.14645,   PubMed: 36106507)
12. Masaki Hanibuchi, Atsuro Saijo, Atsushi Mitsuhashi, Tatsuya Kajimoto, Tetsuya Kitagawa and Yasuhiko Nishioka :
The efficacy of mass screening for chronic obstructive pulmonary disease using screening questionnaires in a medical health check-up population.,
Respiratory Investigation, Vol.60, No.6, 815-821, 2022.
(Tokushima University Institutional Repository: 119053,   DOI: 10.1016/j.resinv.2022.07.005,   PubMed: 36057534)
13. Hiroshi Nokihara, Hirokazu Ogino, Atsushi Mitsuhashi, Kensuke Kondo, Ei Ogawa, Ryohiko Ozaki, Yohei Yabuki, Hiroto Yoneda, Kenji Otsuka and Yasuhiko Nishioka :
Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion.,
BMC Cancer, Vol.22, No.1, 2022.
(Tokushima University Institutional Repository: 117282,   DOI: 10.1186/s12885-022-09701-2,   PubMed: 35650550)
14. Yutaka Morita, Atsuro Saijo, Hiroshi Nokihara, Atsushi Mitsuhashi, Hiroto Yoneda, Kenji Otsuka, Hirokazu Ogino, Yoshimi Bando and Yasuhiko Nishioka :
Radiation therapy induces an abscopal effect and upregulates programmed death-ligand 1 expression in a patient with non-small cell lung cancer.,
Thoracic Cancer, Vol.13, No.7, 1079-1082, 2022.
(Tokushima University Institutional Repository: 117392,   DOI: 10.1111/1759-7714.14330,   PubMed: 35064748)
15. Masahiro Sako, Hiroshi Nokihara, Kensuke Kondo, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Akane Abe, Hiroto Yoneda, Hirokazu Ogino, Kenji Otsuka, Hisanori Uehara and Yasuhiko Nishioka :
A case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia successfully treated with pembrolizumab.,
Thoracic Cancer, Vol.13, No.1, 129-132, 2021.
(Tokushima University Institutional Repository: 117393,   DOI: 10.1111/1759-7714.14243,   PubMed: 34859591)
16. Hiroto Yoneda, Hiroshi Nokihara, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Hirokazu Ogino, Kenji Otsuka and Yasuhiko Nishioka :
Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma.,
BMC Pulmonary Medicine, Vol.21, No.1, 2021.
(Tokushima University Institutional Repository: 117283,   DOI: 10.1186/s12890-021-01746-6,   PubMed: 34781910)
17. Atsushi Mitsuhashi, Kensuke Kondoh, Kazuki Horikawa, Kazuya Koyama, Thi Na Nguyen, Tania Afroj, Hiroto Yoneda, Kenji Otsuka, Hirokazu Ogino, Hiroshi Nokihara, Tsutomu Shinohara and Yasuhiko Nishioka :
Programmed death (PD)-1/PD-ligand 1 blockade mediates antiangiogenic effects by tumor-derived CXCL10/11 as a potential predictive biomarker.,
Cancer Science, Vol.112, No.12, 4853-4866, 2021.
(Tokushima University Institutional Repository: 117305,   DOI: 10.1111/cas.15161,   PubMed: 34628702)
18. Tania Afroj, Atsushi Mitsuhashi, Hirokazu Ogino, Atsuro Saijo, Kenji Otsuka, Hiroto Yoneda, Makoto Tobiume, Thi Na Nguyen, Hisatsugu Goto, Kazuya Koyama, Masamichi Sugimoto, Osamu Kondoh, Hiroshi Nokihara and Yasuhiko Nishioka :
Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes.,
The Journal of Immunology, Vol.206, No.6, 1204-1214, 2021.
(Tokushima University Institutional Repository: 115981,   DOI: 10.4049/jimmunol.2000909,   PubMed: 33504617)
19. Kenji Otsuka, Atsushi Mitsuhashi, Hisatsugu Goto, Masaki Hanibuchi, Kazuya Koyama, Hirohisa Ogawa, Hirokazu Ogino, Atsuro Saijo, Hiroyuki Kozai, Hiroto Yoneda, Makoto Tobiume, Masatoshi Kishuku, Keisuke Ishizawa and Yasuhiko Nishioka :
Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells.,
Lung Cancer, Vol.146, 86-96, 2020.
(Tokushima University Institutional Repository: 115324,   DOI: 10.1016/j.lungcan.2020.05.023,   PubMed: 32526602)

Review, Commentary:

1. Atsushi Mitsuhashi and Yasuhiko Nishioka :
1細胞解析による腫瘍内fibrocyteの同定,
The Cell, Vol.55, No.1, 55-59, Jun. 2023.
2. Atsushi Mitsuhashi and Yasuhiko Nishioka :
血管新生阻害剤に対する耐性獲得メカニズム,
Experimental Medicine, Vol.38, No.15, 157-162, Sep. 2020.
(CiNii: 1010853567272655106)
3. Atsushi Mitsuhashi and Yasuhiko Nishioka :
免疫チェックポイント阻害薬の効果を増強する併用療法,
Respiratory Molecular Medicine, Vol.23, No.1, 49-53, Mar. 2019.
(CiNii: 1521417755561804800)

Proceeding of International Conference:

1. Atsushi Mitsuhashi, Kazuya Koyama, Afroj Tania, Atsuro Saijo, Makoto Tobiume, Hirokazu Ogino, Sugimoto Masamichi, Kondoh Osamu, Hiroshi Nokihara and Yasuhiko Nishioka :
The identification and analysis of fibrocyte regulating the tumor immune microenvironment,
The 9th Joint Meeting 2023 (Tokushima Univ., Gifu Univ., SNU, and IBS-KAIST)., Daejeon, Oct. 2023.
2. Kazuya Koyama, Seidai Satou, Hiroshi Kawano, Hiroshi Kawano, Atsushi Mitsuhashi, Murakami Kojin, Yuya Yamashita, Keiko Haji, Kozo Kagawa, Hirohisa Ogawa and Yasuhiko Nishioka :
Evaluation of fibrocytes in silica-induced and bleomycin-induced pulmonary fibrosis model in mice by single cell RNA-seq analysis,
APSR 2022, Seoul, Nov. 2022.
3. Yabuki Yohei, Kenji Otsuka, Hirokazu Ogino, Takeuchi Eiji, Haku Takashi, Takanori Kanematsu, Nishimura Naoki, Yuko Toyoda, Masaki Hanibuchi, Atsushi Mitsuhashi, Tsukazaki Yuki, Ryohiko Ozaki, Hiroto Yoneda, Hiroshi Nokihara and Yasuhiko Nishioka :
A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with advanced or recurrent non-squamous non-small cell lung cancer,
APSR 2022, Seoul, Nov. 2022.
4. Ryohiko Ozaki, Hiroshi Nokihara, Yabuki Youhei, Atsushi Mitsuhashi, Hiroto Yoneda, Kenji Otsuka, Hirokazu Ogino and Yasuhiko Nishioka :
The examination of the second-line chemotherapy in SCLC patients with interstitial lung disease,
ERS International Congress 2022, Barcelona, Sep. 2022.
5. Kazuya Koyama, Hiroshi Kawano, Atsushi Mitsuhashi, Kojin Murakami, Takeshi Imakura, Yuya Yamashita, Keiko Haji, Kozo Kagawa, Seidai Satou, Hirohisa Ogawa and Yasuhiko Nishioka :
Single Cell RNA-seq Analysis of Fibrocytes in Silica Induced Mouse Pulmonary Fibrosis Model,
ATS 2022 International Conference, San Francisco, May 2022.
6. Nguyen Na Thi, Atsushi Mitsuhashi, Hirokazu Ogino, Hiroyuki Kozai, Hiroto Yoneda, Afroj Tania, Kenji Otsuka, Hiroshi Nokihara and Yasuhiko Nishioka :
S-1 reduces myeloid-derived suppressor cells in murine mesothelioma model and enhances the anti-tumor activity of anti-PD-1 antibody,
APSR 2021, Kyoto and online, Nov. 2021.
7. Ryohiko Ozaki, Hiroshi Nokihara, Atsushi Mitsuhashi, Kondou Kensuke, YABUKI Yohhei, Hiroto Yoneda, Hirokazu Ogino, Kenji Otsuka and Yasuhiko Nishioka :
The clinical efficacy and safety of the second-line chemotherapy in extensive-disease small cell lung cancer patients with interstitial lung disease,
APSR 2021, Kyoto and online, Nov. 2021.
8. Hiroto Yoneda, Hiroshi Nokihara, Atsushi Mitsuhashi, Ryohiko Ozaki, YABUKI Yohhei, Hirokazu Ogino, Kenji Otsuka and Yasuhiko Nishioka :
Association of immune-related adverse events with therapeutic response to Nivolumab in patients with malignant pleural mesothelioma,
APSR 2021, Kyoto and online, Nov. 2021.
9. Hirokazu Ogino, Afroj Tania, Atsushi Mitsuhashi, Atsuro Saijo, Kenji Otsuka, Hiroto Yoneda, Nguyen Thi Na, Kozo Kagawa, Sugimoto Masamichi, Kondoh Osamu, Hiroshi Nokihara and Yasuhiko Nishioka :
Antigen-presenting capacity of fibrocytes and its regulation by anti-PD-1/PD-L1 antibodies,
APSR 2021, Kyoto and online, Nov. 2021.
10. Atsushi Mitsuhashi, Afroj Tania, Atsuro Saijo, Kenji Otsuka, Hiroto Yoneda, Kazuya Koyama, Sugimoto Masamichi, Kondoh Osamu, Hiroshi Nokihara and Yasuhiko Nishioka :
The role of fibrocyte-like cells in combination treatment of immune checkpoint inhibitor with antiangiogenic agents,
ERS International Congress 2020 Virtual, WEB, Sep. 2020.
(DOI: 10.1183/13993003.congress-2020.1134)

Proceeding of Domestic Conference:

1. Yuki Tsukazaki, Hirokazu Ogino, Yoshio Okano, Soji Kakiuchi, Shoko Harada, Yugo Matumura, Seiya Ichihara, Takeshi Imakura, Ryohiko Ozaki, Ei Ogawa, Yutaka Morita, Atsushi Mitsuhashi, Yohei Yabuki, Hiroto Yoneda, Masaki Hanibuchi, Yuko Toyoda, Kayoko Hase, Eiji Takeuchi, Takashi Haku and Yasuhiko Nishioka :
The impacts of G-CSF on the therapeutic efficacy of chemo-immunotherapy for extensive-stage small cell lung cancer.,
2024 the Japanese Society of Medical Oncology Annual Meeting (JSMO2024), Feb. 2024.
2. Hirokazu Ogino, Nguyen Na Thi, Hiroyuki Kozai, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroshi Nokihara, Masaki Hanibuchi and Yasuhiko Nishioka :
Fluoropyrimidine has a potential to be an immunologically optimal partner ofimmunotherapy for thoracic malignancies.,
2024 the Japanese Society of Medical Oncology Annual Meeting (JSMO2024), Feb. 2024.
3. Yuki Tsukazaki, Makoto Tobiume, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Hiroto Yoneda, Hirokazu Ogino, Masaki Hanibuchi, Hirohisa Ogawa, Hiromitsu Takizawa and Yasuhiko Nishioka :
非小細胞肺癌症例における腫瘍浸潤線維細胞の走化因子と疾患予後との関連性についての解析,
第64回日本肺癌学会学術集会, Nov. 2023.
4. Hirokazu Ogino, Hiroyuki Kozai, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Masaki Hanibuchi, Hiroshi Nokihara and Yasuhiko Nishioka :
フッ化ピリミジンは胸部腫瘍の免疫原性細胞死を誘導し免疫チェックポイント阻害薬の至適併用薬となり得る,
第64回日本肺癌学会学術集会, Nov. 2023.
5. Ryohiko Ozaki, Hiroshi Nokihara, Yuki Tsukazaki, Yohei Yabuki, Atsushi Mitsuhashi, Hiroto Yoneda, Hirokazu Ogino and Yasuhiko Nishioka :
進展型小細胞肺癌において2次治療が受けられない患者の臨床的背景の検討,
第64回日本肺癌学会学術集会, Nov. 2023.
6. Atsushi Mitsuhashi, Hirokazu Ogino, Hiroto Yoneda, Hiroshi Nokihara and Yasuhiko Nishioka :
胸部腫瘍におけるfibrocyteの同定と新規治療標的としての展開,
第64回日本肺癌学会学術集会, Nov. 2023.
7. Seidai Satou, Masaki Hanibuchi, Atsushi Mitsuhashi and Yasuhiko Nishioka :
咳喘息治療における効果予測バイオマーカーの探索,
第72回日本アレルギー学会学術大会, Oct. 2023.
8. Ryohiko Ozaki, 小川 瑛, Hiroshi Nokihara, Atsushi Mitsuhashi, Yohei Yabuki, Hiroto Yoneda, Hirokazu Ogino and Yasuhiko Nishioka :
ALK融合遺伝子陽性非小細胞肺癌の効果予測因子に関する検討,
第61回日本癌治療学会学術集会, Oct. 2023.
9. Yohei Yabuki, Atsushi Mitsuhashi, Hirokazu Ogino, Na Thi Nguyen, Hiroto Yoneda, Ryohiko Ozaki, Yuki Tsukazaki, Masaki Hanibuchi, Hiroshi Nokihara and Yasuhiko Nishioka :
HIF1A 阻害による腫瘍細胞由来 CXCL10/11 制御を介した抗 PDL1 抗体への耐性克服,
第82回日本癌学会学術総会, Sep. 2023.
10. Atsushi Mitsuhashi, Kazuya Koyama, Hirokazu Ogino, 杉本 正道, 根東 攝, Hiroshi Nokihara and Yasuhiko Nishioka :
腫瘍内 fibrocyte 遊走・分化制御がもたらす腫瘍免疫微小環境への影響,
第82回日本癌学会学術総会, Sep. 2023.
11. Atsushi Mitsuhashi, Kazuya Koyama, アフローズ タニア, Atsuro Saijo, Makoto Tobiume, Hirokazu Ogino, 杉本 正道, 根東 攝, Hiroshi Nokihara and Yasuhiko Nishioka :
腫瘍内 fibrocyte の同定と制御による新規がん治療開発への橋渡し研究,
第82回日本癌学会学術総会, Sep. 2023.
12. Atsushi Mitsuhashi, Hirokazu Ogino, Na Thi Nguyen, 矢葺 洋平, Hiroto Yoneda, 杉本 正道, 根東 攝, Hiroshi Nokihara and Yasuhiko Nishioka :
腫瘍内fibrocyteの同定と機能制御による新規複合がん免疫療法の開発,
第32回日本がん転移学会学術集会・総会, Jul. 2023.
13. Hiroto Yoneda, Atsushi Mitsuhashi, Hirokazu Ogino, Hiroshi Nokihara, Shinji Abe, 金子 美華, 加藤 幸成 and Yasuhiko Nishioka :
悪性胸膜中皮腫に対する抗ポドプラニン抗体および抗CTLA-4抗体による複合がん免疫療法の検討,
第32回日本がん転移学会学術集会・総会, Jul. 2023.
14. Yuki Tsukazaki, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohhei Yabuki, Hiroto Yoneda, Hirokazu Ogino and Yasuhiko Nishioka :
肺癌における腫瘍浸潤線維細胞の走化因子とその疾患予後に及ぼす影響についての解析,
第27回日本がん分子標的治療学会学術集会, Jun. 2023.
15. Atsushi Mitsuhashi, Hirokazu Ogino, Na Thi Nguyen, Hiroto Yoneda, Yohhei Yabuki, 杉本 正道, 根東 攝, Hiroshi Nokihara and Yasuhiko Nishioka :
Fibrocyte の分化制御による複合がん免疫療法への展開,
第27回日本がん分子標的治療学会学術集会, Jun. 2023.
16. Yohhei Yabuki, Atsushi Mitsuhashi, Na Thi Nguyen, Hirokazu Ogino, Hiroto Yoneda, Ryohiko Ozaki and Yasuhiko Nishioka :
IFN-g 反応性ケモカイン産生制御機序の解明と新規複合がん免疫療法への応用,
第27回日本がん分子標的治療学会学術集会, Jun. 2023.
17. Seidai Satou, Masaki Hanibuchi, Atsushi Mitsuhashi and Yasuhiko Nishioka :
咳喘息における呼気中一酸化窒素と血清ペリオスチンの臨床的意義の検討,
第63回日本呼吸器学会学術講演会, Apr. 2023.
18. Masaki Hanibuchi, Atsushi Mitsuhashi, Atsuro Saijo, Seidai Satou and Yasuhiko Nishioka :
スクリーニング質問票を用いたCOPD検診システムの有用性の検討,
第63回日本呼吸器学会学術講演会, Apr. 2023.
19. Hirokazu Ogino, Ryohiko Ozaki, Kenji Otsuka, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohhei Yabuki, Hiroto Yoneda, Hiroshi Nokihara and Yasuhiko Nishioka :
間質性肺炎を合併する進行期肺癌に対する二次化学療法の有効性および安全性に関する検討,
第120回日本内科学会講演会, Apr. 2023.
20. Tsukazaki Yuki, Ogawa Ei, Hiroshi Nokihara, Atsushi Mitsuhashi, Kondo Kensuke, Yabuki Youhei, Ryohiko Ozaki, Hiroto Yoneda, Hirokazu Ogino and Yasuhiko Nishioka :
The prognostic factors for the efficacy of anaplastic lymphoma kinase inhibitors in non-small cell lung cancer,
2023 the Japanese Society of Medical Oncology Annual Meeting, Mar. 2023.
21. Ryohiko Ozaki, Hiroshi Nokihara, Tukazaki Yuki, Yabuki Yohei, Atsushi Mitsuhashi, Hiroto Yoneda, Hirokazu Ogino and Yasuhiko Nishioka :
Clinical factors of not receiving second-line chemotherapy in ED-SCLC patients,
2023 the Japanese Society of Medical Oncology Annual Meeting, Mar. 2023.
22. Hirokazu Ogino, Kondo Kensuke, Atsushi Mitsuhashi, Tsukazaki Yuki, Ryohiko Ozaki, Yabuki Yohei, Hiroto Yoneda, Hiroshi Nokihara and Yasuhiko Nishioka :
The novel prognostic system for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer,
2023 the Japanese Society of Medical Oncology Annual Meeting, Mar. 2023.
23. 中西 颯斗, Keiko Haji, 松村 有悟, Atsushi Mitsuhashi, 小川 瑛, Takeshi Imakura, 美馬 正人, Ryohiko Ozaki, Hiroto Yoneda, Hirokazu Ogino, Satoshi Sakaguchi, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka :
同時に異なる3つの組織型を認めた多発性肺癌の1例,
第67回日本呼吸器学会中国・四国地方会, Dec. 2022.
24. 小川 瑛, Hiroshi Nokihara, Atsushi Mitsuhashi, 近藤 健介, Yuki Tsukazaki, Yohhei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Hirokazu Ogino and Yasuhiko Nishioka :
ALK融合遺伝子陽性非小細胞肺癌の効果予測因子に関する検討,
第63回日本肺癌学会学術集会, Dec. 2022.
25. Na T. Nguyen, Atsushi Mitsuhashi, Hirokazu Ogino, Hiroyuki Kozai, Hiroto Yoneda, Hiroshi Nokihara and Yasuhiko Nishioka :
Eliminates MDSCs and enhances the efficacy of immune checkpoint inhibitor in thoracic tumors,
The 63rd Annual Meeting of the Japan Lung Cancer Society, Dec. 2022.
26. Hiroshi Nokihara, Hirokazu Ogino, Atsushi Mitsuhashi, 近藤 健介, 小川 瑛, Ryohiko Ozaki, Yohhei Yabuki, Hiroto Yoneda and Yasuhiko Nishioka :
胸水を伴うEGFR遺伝子変異陽性非小細胞肺がんに対するオシメルチニブの有効性の検討,
第63回日本肺癌学会学術集会, Dec. 2022.
27. Ryohiko Ozaki, Hiroshi Nokihara, Yuki Tsukazaki, Yohhei Yabuki, Atsushi Mitsuhashi, Hiroto Yoneda, Hirokazu Ogino and Yasuhiko Nishioka :
間質性肺炎合併進展型小細胞肺癌における2次化学療法の有効性および安全性について,
第60回日本癌治療学会学術集会, Oct. 2022.
28. Atsushi Mitsuhashi, Hirokazu Ogino, Hiroshi Nokihara and Yasuhiko Nishioka :
PD-1/PD-L1 blockade mediates antiangiogenic effects by tumorderived CXCL10/11 as a potential predictive biomarker,
The 81st Annual Meeting of the Japanese Cancer Association, Sep. 2022.
29. Atsushi Mitsuhashi, Hirokazu Ogino, Sugimoto Masamichi, Hiroshi Nokihara and Yasuhiko Nishioka :
Fibrocyte drives antitumor immunity via T cell-costimulation in combination immunotherapy,
The 81st Annual Meeting of the Japanese Cancer Association, Sep. 2022.
30. Atsushi Mitsuhashi, Hirokazu Ogino, Na Thi Nguyen, Hiroto Yoneda, Kenji Otsuka, 杉本 正道, 根東 攝, Hiroshi Nokihara and Yasuhiko Nishioka :
免疫チェックポイント阻害薬および血管新生阻害薬併用療法における腫瘍内fibrocyteの機能解析,
第26回日本がん分子標的治療学会学術集会, Jun. 2022.
31. Hiroto Yoneda, Atsushi Mitsuhashi, Hirokazu Ogino, Ryohiko Ozaki, Yohhei Yabuki, Hiroshi Nokihara, Shinji Abe, 加藤 幸成 and Yasuhiko Nishioka :
悪性胸膜中皮腫に対する抗ポドプラニン抗体および抗CTLA-4抗体による複合がん免疫療法の検討,
第26回日本がん分子標的治療学会学術集会, Jun. 2022.
32. Kojin Murakami, 原田 紗希, Takeshi Imakura, Atsushi Mitsuhashi, 小川 瑛, TSUKAZAKI Yuki, Ryohiko Ozaki, YABUKI Yohhei, Kozo Kagawa, Hiroto Yoneda, Akane Abe, Hirokazu Ogino, Kazuya Koyama, Seidai Satou, Satoshi Sakaguchi and Yasuhiko Nishioka :
抗GM-CSF抗体測定が早期診断に有用であった自己免疫性肺胞蛋白症の一例,
第45回日本呼吸器内視鏡学会学術集会, May 2022.
33. Takeshi Imakura, Seidai Satou, 原田 紗希, Atsushi Mitsuhashi, 小川 瑛, Kojin Murakami, Yuki Tsukazaki, Ryohiko Ozaki, Yohhei Yabuki, Kozo Kagawa, Hiroto Yoneda, Akane Abe, Hirokazu Ogino, Satoshi Sakaguchi and Yasuhiko Nishioka :
肺門部・縦隔リンパ節腫大に対してEBUS-TBNAを実施し子宮頸癌再発と診断した1例,
第45回日本呼吸器内視鏡学会学術集会, May 2022.
34. Kazuya Koyama, Atsushi Mitsuhashi, Takeshi Imakura, Kojin Murakami, Kozo Kagawa, Seidai Satou, Hiroshi Kawano, Hirohisa Ogawa and Yasuhiko Nishioka :
シングルセル解析を用いた肺線維症マウスモデルにおけるfibrocyteの検討,
第62回日本呼吸器学会学術講演会, Apr. 2022.
35. Ryohiko Ozaki, Hiroshi Nokihara, YABUKI Yohhei, Atsushi Mitsuhashi, Hiroto Yoneda, Kenji Otsuka, Hirokazu Ogino and Yasuhiko Nishioka :
Second-line chemotherapy for extensive-disease small cell lung cancer with interstitial lung disease,
第19回日本臨床腫瘍学会学術集会, Feb. 2022.
36. Atsushi Mitsuhashi, Hirokazu Ogino, Hiroto Yoneda, Kenji Otsuka, Hiroshi Nokihara and Yasuhiko Nishioka :
抗PD-1/PD-L1抗体による血管新生制御メカニズムの解析と治療効果予測バイオマーカーとしての応用,
第62回日本肺癌学会学術集会, Nov. 2021.
37. Ryohiko Ozaki, Hiroshi Nokihara, Atsushi Mitsuhashi, 近藤 健介, YABUKI Yohhei, Hiroto Yoneda, Hirokazu Ogino, Kenji Otsuka and Yasuhiko Nishioka :
間質性肺炎合併小細胞肺癌に対する二次化学療法の有効性及び安全性の検討,
第62回日本肺癌学会学術集会, Nov. 2021.
38. Hiroto Yoneda, Hiroshi Nokihara, Atsushi Mitsuhashi, Ryohiko Ozaki, YABUKI Yohhei, Hirokazu Ogino, Kenji Otsuka and Yasuhiko Nishioka :
悪性胸膜中皮腫患者におけるニボルマブの免疫関連有害事象と治療効果の相関性,
第59回日本癌治療学会学術集会, Oct. 2021.
39. Kenji Otsuka, Atsushi Mitsuhashi, Ryohiko Ozaki, YABUKI Yohhei, Hiroto Yoneda, Hirokazu Ogino, Hiroshi Nokihara, 竹内 栄治, 杉浦 八十生, 知花 賢治, 田村 厚久, 安宅 信二 and Yasuhiko Nishioka :
進展型小細胞肺癌における予後規定因子,
第59回日本癌治療学会学術集会, Oct. 2021.
40. Atsushi Mitsuhashi, Hirokazu Ogino, Atsuro Saijo, Kenji Otsuka, 杉本 正道, Hiroshi Nokihara and Yasuhiko Nishioka :
免疫チェックポイント阻害薬および血管新生阻害薬併用療法におけるfibrocyteの役割,
第80回日本癌学会学術総会, Oct. 2021.
41. 中内 友合江, YABUKI Yohhei, Keiko Haji, Hiroto Yoneda, Atsushi Mitsuhashi, 青井 優, 石田 卓也, 村上 尚哉, Hirokazu Ogino, Seidai Satou, Hiroshi Nokihara and Yasuhiko Nishioka :
Tepotinibが著効したMET遺伝子exon14 skipping変異陽性肺腺癌の1例,
第59回日本肺癌学会中国・四国支部学術集会, Aug. 2021.
42. Atsushi Mitsuhashi, Hirokazu Ogino, Hiroto Yoneda, Kenji Otsuka, Hiroshi Nokihara and Yasuhiko Nishioka :
肺がん肝転移におけるspheroid形成がん幹細胞様分画の役割,
第30回日本がん転移学会学術集会・総会, Jul. 2021.
43. Atsushi Mitsuhashi, Tania Afroj, Na Thi Nguyen, Hirokazu Ogino, Hiroto Yoneda, Kenji Otsuka, Hiroshi Nokihara and Yasuhiko Nishioka :
抗PD-1/PD-L1抗体による腫瘍血管新生抑制メカニズムの解析と治療効果予測バイオマーカーとしての応用.,
第25回日本がん分子標的治療学会学術集会, May 2021.
44. Na Thi Nguyen, Atsushi Mitsuhashi, Hiroyuki Kozai, Hiroto Yoneda, Afroj Tania, Kenji Otsuka, Hiroshi Nokihara and Yasuhiko Nishioka :
TS-1による腫瘍関連骨髄由来抑制細胞の制御を介した免疫チェックポイント阻害剤との併用効果の検討,
第25回日本がん分子標的治療学会学術集会, May 2021.
45. 近藤 健介, Hiroshi Nokihara, Seidai Satou, Atsushi Mitsuhashi, Hiroto Yoneda, Hiroyuki Kozai, Kenji Otsuka and Yasuhiko Nishioka :
非小細胞肺癌に対する免疫チェックポイント阻害剤の予後予測因子の検討,
第61回日本呼吸器学会学術講演会, Apr. 2021.
46. Hiroyuki Kozai, Atsushi Mitsuhashi, Ryohiko Ozaki, Hiroto Yoneda, Kenji Otsuka, Hiroshi Nokihara and Yasuhiko Nishioka :
免疫原性細胞死を誘導する細胞傷害性抗癌剤についての検討,
第61回日本呼吸器学会学術講演会, Apr. 2021.
47. 尾崎 領彦, Atsushi Mitsuhashi, Hiroto Yoneda, Kenji Otsuka, Hiroshi Nokihara, Yasuhiko Nishioka, 櫻田 巧 and Keisuke Ishizawa :
ペメトレキセド投与後の皮疹に対するデキサメタゾン予防投与の効果の検討,
第18回日本臨床腫瘍学会学術集会, Feb. 2021.
48. Atsushi Mitsuhashi, 櫻田 巧, Mitsuhiro Goda, Yoshito Zamami, Hiroto Yoneda, Kenji Otsuka, Hiroshi Nokihara, Keisuke Ishizawa and Yasuhiko Nishioka :
ペメトレキセド投与後の皮疹に対する低用量デキサメタゾン予防効果の検討,
第61回日本肺癌学会学術集会, Nov. 2020.
49. Kenji Otsuka, Atsushi Mitsuhashi, Hiroto Yoneda, Hiroshi Nokihara, 竹内 栄治, 知花 賢治, 安宅 信二, 田村 厚久 and Yasuhiko Nishioka :
進展型小細胞肺癌の予後規定因子の検討,
第61回日本肺癌学会学術集会, Nov. 2020.
50. 櫻田 巧, Atsushi Mitsuhashi, Hiroto Yoneda, Kenji Otsuka, Mitsuhiro Goda, Yoshito Zamami, Keisuke Ishizawa, Hiroshi Nokihara and Yasuhiko Nishioka :
ペメトレキセド投与後の皮疹に対する低用量のステロイド予防投与の前向き臨床試験,
第58回日本癌治療学会学術集会, Oct. 2020.
51. Hiroyuki Kozai, Atsushi Mitsuhashi, Hiroto Yoneda, Kenji Otsuka, Hiroshi Nokihara and Yasuhiko Nishioka :
細胞障害性抗がん剤による腫瘍免疫原性細胞死誘導能の検討,
第58回日本癌治療学会学術集会, Oct. 2020.
52. Atsuro Saijo, Hiroyuki Kozai, Hisatsugu Goto, Kenji Otsuka, Hiroto Yoneda, Atsushi Mitsuhashi and Yasuhiko Nishioka :
非小細胞肺がんに合併した悪性胸水に対する bevacizumab の有効性と耐性化機序の解析,
第24回日本がん分子標的治療学会学術集会, Oct. 2020.
53. NGUYEN NA THI, Atsushi Mitsuhashi, Tania Afroj, Hiroto Yoneda, Hiroyuki Kozai, Kenji Otsuka, Hiroshi Nokihara and Yasuhiko Nishioka :
マウス中皮腫細胞株皮下移植モデルにおける細胞障害性抗癌剤の腫瘍関連骨髄由来抑制細胞への影響,
第24回日本がん分子標的治療学会学術集会, Oct. 2020.
54. Tania Afroj, Hirokazu Ogino, Atsushi Mitsuhashi, Hiroto Yoneda, Hiroyuki Kozai, Kenji Otsuka, Hiroshi Nokihara, Masahiro Abe and Yasuhiko Nishioka :
腫瘍免疫における線維細胞の免疫調節機能の検討,
第24回日本がん分子標的治療学会学術集会, Oct. 2020.
55. 近藤 健介, Hiroshi Nokihara, Atsushi Mitsuhashi, Hiroto Yoneda, Hiroyuki Kozai, Kenji Otsuka and Yasuhiko Nishioka :
非小細胞肺癌における免疫チェックポイント阻害剤の予後予測因子の検討,
第24回日本がん分子標的治療学会学術集会, Oct. 2020.
56. Atsushi Mitsuhashi, Tania Afroj, Hirokazu Ogino, NGUYEN NA THI, Hiroto Yoneda, Hiroyuki Kozai, Kenji Otsuka, 杉本 正道, 根東 攝, Hiroshi Nokihara and Yasuhiko Nishioka :
免疫チェックポイント阻害薬および血管新生阻害薬併用療法における腫瘍内 fibrocyte-like cell の機能解析,
第24回日本がん分子標的治療学会学術集会, Oct. 2020.
57. Hiroyuki Kozai, Atsushi Mitsuhashi, NGUYEN NA THI, Tania Afroj, Hiroto Yoneda, Kenji Otsuka, Hiroshi Nokihara and Yasuhiko Nishioka :
肺癌において細胞障害性抗癌剤が免疫原性細胞死に与える影響についての検討,
第24回日本がん分子標的治療学会学術集会, Oct. 2020.
58. Atsushi Mitsuhashi, Hirokazu Ogino, Atsuro Saijo, Kenji Otsuka, 杉本 正道, Hiroshi Nokihara and Yasuhiko Nishioka :
免疫チェックポイント阻害薬および血管新生阻害薬併用療法における腫瘍内 fibrocyte-like cell の機能解析,
第79回日本癌学会学術総会, Oct. 2020.
59. Yasuhiko Nishioka, Kazuya Koyama, Atsushi Mitsuhashi, Afroj Tania and Hiroshi Kawano :
肺線維症モデルにおけるscRNA-Seqを用いた線維細胞の解析,
第60回日本呼吸器学会学術講演会(シンポジウム), Sep. 2020.
60. Atsushi Mitsuhashi, Hirokazu Ogino, 木宿 昌俊, Kenji Otsuka, Hiroshi Nokihara and Yasuhiko Nishioka :
免疫チェックポイント阻害薬および血管新生阻害薬による複合がん免疫療法における腫瘍内fibrocytelike cellの機能解析,
第32回日本バイオセラピィ学会学術集会総会, Nov. 2019.
61. Kenji Otsuka, Hiroto Yoneda, Atsushi Mitsuhashi, Hirokazu Ogino, Hiroyuki Kozai, Makoto Tobiume, Hiroshi Nokihara and Yasuhiko Nishioka :
間質性肺炎合併非小細胞肺癌における2次化学療法の安全性と有効性の検討,
第57回日本癌治療学会学術集会, Oct. 2019.
62. Yasuhiko Nishioka, Hirokazu Ogino and Atsushi Mitsuhashi :
血管新生阻害薬耐性とその克服,
第23回日本がん分子標的治療学会学術集会(シンポジウム), Jun. 2019.
63. Atsushi Mitsuhashi, Hisatsugu Goto, Hirokazu Ogino, Kenji Otsuka, 杉本 正道, 根東 攝 and Yasuhiko Nishioka :
免疫チェックポイント阻害薬および血管新生阻害薬併用療法における fibrocyte-like cell の機能解析,
第23回日本がん分子標的治療学会学術集会, Jun. 2019.
64. Atsushi Mitsuhashi, Makoto Tobiume, Hirokazu Ogino, Mayo Kondou, Yuko Toyoda, Hisatsugu Goto, Mitsuteru Yoshida, Hirohisa Ogawa, Hiroshi Nokihara and Yasuhiko Nishioka :
肺多形癌における上皮間葉転換 (EMT)の検討,
第120回日本内科学会四国地方会, May 2019.
65. Afroj Tania, Hirokazu Ogino, Makoto Tobiume, Hiroto Yoneda, Kisyuku Masatoshi, Atsuro Saijo, Atsushi Mitsuhashi, Koyama Kazuya, Hisatsugu Goto and Yasuhiko Nishioka :
Analyses of immuno-modulatory function of fibrocytes in tumor immunity,
The 59th Annual Meeting of the Japanese Respiratory Society, Apr. 2019.
66. Hirokazu Ogino, Kenji Otsuka, Atsushi Mitsuhashi, 木宿 昌俊 and Yasuhiko Nishioka :
肺癌・悪性胸膜中皮腫マウスモデルを用いた免疫チェックポイント阻害薬と化学療法の併用効果に関する検討,
第31回日本バイオセラピィ学会学術集会総会, Dec. 2018.
67. Hisatsugu Goto, Atsushi Mitsuhashi, Atsuro Saijo and Yasuhiko Nishioka :
線維細胞(fibrocytes)を標的とした血管新生阻害薬耐性メカニズムの解明と治療への展開,
第59回日本肺癌学会学術集会, Nov. 2018.
68. Naoki Takahashi, Hirokazu Ogino, Masaki Hanibuchi, Atsuro Saijo, Makoto Tobiume, Hiroyuki Kozai, Hiroto Yoneda, Asami Fukuya, Atsushi Mitsuhashi, 宮本 憲哉, Hiroshi Nokihara, Hisatsugu Goto and Yasuhiko Nishioka :
当科における高齢者肺癌の臨床的検討,
第257回徳島医学会学術集会, Aug. 2018.
69. Atsushi Mitsuhashi, Kozo Kagawa, Hiroto Yoneda, Atsuro Saijo, Makoto Tobiume, Hirokazu Ogino, Mayo Kondou, Naoki Takahashi, Hiroshi Nokihara, Hisatsugu Goto and Yasuhiko Nishioka :
当科における免疫チェックポイント阻害薬による薬剤性間質性肺疾患の検討,
第59回日本呼吸器学会中国・四国地方会/第57回日本肺癌学会中国・四国支部学術集会, Jul. 2018.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

  • ヘパラナーゼ制御によるhot tumor誘導と新規がん複合免疫療法の創出 (Project/Area Number: 24K10287 )
  • 腫瘍内線維細胞における時計遺伝子の機能解析と新規複合がん免疫療法開発への応用 (Project/Area Number: 23K06637 )
  • 肺がん・中皮腫における新たな抗原提示細胞の同定から革新的複合がん免疫療法への展開 (Project/Area Number: 23K24340 )
  • 腫瘍内免疫療法を用いた新規複合がん免疫療法の効果規定因子を同定する試み (Project/Area Number: 22K07304 )
  • Anti-angiogenic effects of PD-L1 blockade as a potential predictive biomarker (Project/Area Number: 21K15488 )
  • Development of biomarkers related to drug resistance of angiogenesis inhibitors (Project/Area Number: 20K08542 )
  • The role of fibrocyte in combination treatment of immune checkpoint inhibitor with antiangiogenic agents (Project/Area Number: 19K16746 )
  • Development of novel combination immunotherapy against lung cancer and mesothelioma: establishment of immunological basis for clinic (Project/Area Number: 19H03668 )
  • Search by Researcher Number (00833732)